Press Releases

LabStyle Innovations Announces the Initial Launch of the Dario™ Diabetes Management Solution for Android Devices

Dario™ mobile application for Android is now available for free download in the UK, New Zealand and other initial markets

The Dario™ Smart Meter for Android to be available in September

Jul 31, 2014

CAESAREA, Israel, July 31, 2014 /PRNewswire/ -- LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, announced today that the company has released the Dario™ Diabetes Management App for Android smartphone users.  The mobile application will have the same user interface and features as the iOS Dario™ Application and will be available in select soft launch markets, including the United Kingdom and New Zealand.

The launch of the Dario™ App for Android represents the achievement of another milestone for LabStyle in its strategic worldwide rollout plan for Dario™ and follows the launch of the iOS Dario™ App in late 2013 and in the initial soft launch of the full Dario™ Diabetes Management Solution for iOS that has been ongoing in select jurisdictions during 2014.  The release of the Android application is the next step in bringing Dario™ mobile diabetes management to diabetics worldwide, now also including 80% of the smartphone market who are Android device users according to IDC Research.  The launch of the Android application precedes the anticipated September launch of the Dario™ Smart Meter for Android users.

The Dario™ application lets people with diabetes easily track their blood sugars, food (Lab Style's database has nutritional data on over 220,000 items), insulin and activity affecting their sugar levels. Personalized reports help people with diabetes understand why their sugars change and what to do next.

Dario™ is a cloud-based, diabetes management solution which includes novel software applications combined with the stylish, 'all-in-one', pocket-sized, Dario™ smart meter which interfaces with a user's mobile device to form the overall Dario™ Diabetes Management Solution, allowing diabetics to monitor their blood sugars and other activities and gain insights into managing their disease using their mobile devices. 

"We have been working very hard to bring to the market the much anticipated Dario application to diabetics with Android devices, and we are delighted with the market demand for this solution demonstrated in the initial territories where we have marketed Dario and users have long-awaited our Android version," said Erez Raphael, LabStyle Innovations President and Chief Executive Officer.  He continued, "The potential Android market for Dario is immense, and we are very pleased that we will now be able to widen our market extensively by offering Dario to this large population of smartphone users so that they too can benefit from the Dario personalized information and community support to make their lives easier with diabetes."

About LabStyle Innovations

LabStyle Innovations Corp. (OTCQB:DRIO) develops and commercializes patented technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle's flagship product is the Dario™ Diabetes Management Solution, a mobile, cloud-based, diabetes management solution which includes novel software applications combined with a stylish, 'all-in-one', pocket-sized, blood glucose monitoring device.  Dario™ received CE mark certification in September 2013 and began a world rollout in select countries in December 2013.  LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario™™ smart meter (Dario™ Blood Glucose Monitoring System) in December 2013. LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services and in April 2014, LabStyle received a Notice of Allowance for a U.S. patent covering core functions of the Dario™ Blood Glucose Monitoring System.  For more information: www.myDario™.com and http://myDario™

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the "Company") related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the results of the Company's sales, marketing and regulatory efforts with both the iOS and Android versions of Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

© LabStyle Innovations Corp.  All rights reserved.



Investor Relations

Brenda Zeitlin

LabStyle Innovations

Booke and Company Inc.

1 212 490 9095

972 54 3304831

SOURCE LabStyle Innovations Corp.